A retrospective claims analysis of 2897 matched pairs found hazard ratios of 0.48 to 0.67 for new atopic disease with dupilumab vs systemic corticosteroids in children.
|Videos|June 24, 2022
Environmental Factors of Atopic Dermatitis
Author(s)Linda Stocum, Associate Editor
Eric Simpson, MD, MCR, director of clinical research and dermatology professor at the Frances J. Storrs medical school at Oregon Health & Science University in Portland, Oregon, details the environment factors that could impact atopic dermatitis.
Advertisement
Advertisement
Related to this article
SYX-5219 improved disease severity and itch in a Phase 1b trial of adults with moderate to severe atopic dermatitis.
Christophe Piketty discusses 3-year ARCADIA data demonstrating sustained efficacy and long-term safety of nemolizumab in atopic dermatitis.
No skin lesion flares were observed through 16 weeks after switching from dupilumab to upadacitinib; itch flares occurred in 3.6% to 4.8% of patients with baseline WP-NRS scores of 6 or lower.
Three-year ARCADIA LTE data show sustained skin clearance and itch control with nemolizumab in moderate-to-severe atopic dermatitis.
Upadacitinib showed broader inflammatory effects and earlier skin barrier restoration than dupilumab in atopic dermatitis.
Advertisement
Advertisement
Trending on Dermatology Times
1
Bitopertin Meets All End Points in Phase 3 APOLLO Trial for EPP
2
Dupilumab Associated With Lower Atopic March Risk in Pediatric Atopic Dermatitis
3
Social Media Mythbusters: Can Castor Oil Really Grow Hair?
4
EADV 2026 Atopic Dermatitis Highlights: Tilrekimig, RAC2 Inhibition, and Level Up Data
5